Inventor · disambiguated record
Walter Strapps
Also filed as: STRAPPS WALTER · STRAPPS WALTER R · STRAPPS WALTER RICHARD
21 granted patents·37 pending applications·107 citations·filing 2004–2025
94Inventor score
Files withSIRNA THERAPEUTICS INC18INTELLIA THERAPEUTICS INC14JADHAV VASANT5MERCK & CO INC5PICKERING VICTORIA5
Top patents by PatentIndex Score
58 records- 0193US11479767B2Modified guide RNAsINTELLIA THERAPEUTICS INC·Filed 2019·Granted Oct 25, 2022·12 cites·27 claims
- 0293US8835623B2RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)SIRNA THERAPEUTICS INC·Filed 2013·Granted Sep 16, 2014·15 cites·20 claims
- 0391US8518907B2RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)BROWN DUNCAN·Filed 2011·Granted Aug 27, 2013·16 cites·17 claims
- 0489US11795460B2Compositions and methods for TTR gene editing and treating ATTR amyloidosisINTELLIA THERAPEUTICS INC·Filed 2022·Granted Oct 24, 2023·1 cites·24 claims
- 0589US9850491B2RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)SIRNA THERAPEUTICS INC·Filed 2016·Granted Dec 26, 2017·5 cites·15 claims
- 0688US2024247271A1Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)SIRNA THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 0787US10729787B2Systemic delivery of myostatin short interfering nucleic acids (siNA) conjugated to a lipophilic moietySIRNA THERAPEUTICS INC·Filed 2018·Granted Aug 4, 2020·2 cites·12 claims
- 0887US9447420B2RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (SINA)SIRNA THERAPEUTICS INC·Filed 2014·Granted Sep 20, 2016·6 cites·39 claims
- 0987US7049076B2Method for assaying protein—protein interactionUNIV COLUMBIA·Filed 2004·Granted May 23, 2006·28 cites·42 claims
- 1087US2025066791A1Rna interference mediated inhibition of prolyl hydroxylase domain 2 (phd2) gene expression using short interfering nucleic acid (sina)SIRNA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1186US10577606B2RNA interference mediated inhibition of prolyl hydroxylase domain 2 (PHD2) gene expression using short interfering nucleic acid (siNA)SIRNA THERAPEUTICS INC·Filed 2017·Granted Mar 3, 2020·2 cites·14 claims
- 1285US2025059532A1Modified Guide RNAsINTELLIA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1384US9233997B2RNA interference mediated inhibition of prolyl hydroxylase domain 2 (PHD2) gene expression using short interfering nucleic acid (siNA)ASON BRANDON·Filed 2011·Granted Jan 12, 2016·7 cites·11 claims
- 1484US8017398B2Method for assaying protein-protein interactionLIFE TECHNOLOGIES CORP·Filed 2006·Granted Sep 13, 2011·8 cites·23 claims
- 1583US11549107B2Compositions and methods for treating alpha-1 antitrypsin deficiencyINTELLIA THERAPEUTICS INC·Filed 2019·Granted Jan 10, 2023·2 cites·21 claims
- 1682US11332745B2RNA interference mediated inhibition of prolyl hydroxylase domain 2 (PHD2) gene expression using short interfering nucleic acid (SINA)SIRNA THERAPEUTICS INC·Filed 2020·Granted May 17, 2022·1 cites·13 claims
- 1781US2025207130A1Compositions and Methods for TTR Gene Editing and Treating ATTR AmyloidosisINTELLIA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1880US11952573B2RNA interference mediated inhibition of prolyl hydroxylase domain 2 (PHD2) gene expression using short interfering nucleic acid (siNA)SIRNA THERAPEUTICS INC·Filed 2022·Granted Apr 9, 2024·0 cites·12 claims
- 1979US12173284B2Modified guide RNAsINTELLIA THERAPEUTICS INC·Filed 2022·Granted Dec 24, 2024·0 cites·31 claims
- 2079US2023144623A1Systemic delivery of myostatin short interfering nucleic acids (sina) conjugated to a lipophilic moietySIRNA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2177US11965165B2Compositions and methods for TTR gene editing and treating ATTR amyloidosisINTELLIA THERAPEUTICS INC·Filed 2022·Granted Apr 23, 2024·0 cites·21 claims
- 2277US2023030119A1Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)SIRNA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2376US10004814B2Systemic delivery of myostatin short interfering nucleic acids (siNA) conjugated to a lipophilic moietySIRNA THERAPEUTICS INC·Filed 2014·Granted Jun 26, 2018·2 cites·14 claims
- 2473US12460205B2Compositions and methods for treating alpha-1 antitrypsin deficiencyINTELLIA THERAPEUTICS INC·Filed 2022·Granted Nov 4, 2025·0 cites·18 claims
- 2572US11529428B2Systemic delivery of myostatin short interfering nucleic acids (siNA) conjugated to a lipophilic moietySIRNA THERAPEUTICS INC·Filed 2020·Granted Dec 20, 2022·0 cites·16 claims
- 2672US2025312490A1Systemic delivery of myostatin short interfering nucleic acids (sina) conjugated to a lipophilic moietySIRNA THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2771US2024124897A1Compositions and Methods Comprising a TTR Guide RNA and a Polynucleotide Encoding an RNA-Guided DNA Binding AgentINTELLIA THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2868US2019330639A1Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)SIRNA THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 2966US10246714B2RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)SIRNA THERAPEUTICS INC·Filed 2017·Granted Apr 2, 2019·0 cites·23 claims
- 3063US2020248180A1Compositions and Methods for TTR Gene Editing and Treating ATTR AmyloidosisINTELLIA THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3162US2023044994A1Compositions and Methods Comprising a TTR Guide RNA and a Polynucleotide Encoding an RNA-Guided DNA Binding AgentINTELLIA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3261US2016298123A1Rna interference mediated inhibition of prolyl hydroxylase domain 2 (phd2) gene expression using short interfering nucleic acid (sina)SIRNA THERAPEUTICS INC·Filed 2015·Application pending·0 cites
- 3358US2010137406A1RNA Interference Mediated Inhibition of Cyclic Nucleotide Type 4 Phosphodiesterase (PDE4B) Gene Expression Using Short Interfering Nucleic Acid (siNA)MERCK & CO INC·Filed 2008·Application pending·0 cites
- 3457US2021222173A1Compositions and Methods for Lactate Dehydrogenase (LDHA) Gene EditingINTELLIA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3555US2023035659A1Compositions and Methods for TTR Gene Editing and Treating ATTR Amyloidosis Comprising a Corticosteroid or Use ThereofINTELLIA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3655US2021163943A1Compositions and Methods for Hydroxyacid Oxidase 1 (HAO1) Gene Editing for Treating Primary Hyperoxaluria Type 1 (PH1)INTELLIA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3754US2012077706A1Method for assaying protein-protein interactionLEE KEVIN J·Filed 2011·Application pending·0 cites
- 3851US2020291427A1Crispr-based therapeutics for targeting htra1 and methods of useGEMINI THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 3951US2011288154A1RNA Interference Mediated Inhibition of Epithelial Sodium Channel (ENaC) Gene Expression Using Short Interfering Nucleic Acid (siNA)STRAPPS WALTER·Filed 2009·Application pending·0 cites
- 4051US2020270614A1RNAi-BASED THERAPEUTICS FOR TARGETING HTRA1 AND METHODS OF USEGEMINI THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 4150US2010137405A1RNA Interference Mediated Inhibition of Cyclic Nucleotide Type 4 Phosphodiesterase (PDE4B) Gene Expression Using Short Interfering Nucleic Acid (siNA)MERCK & CO INC·Filed 2008·Application pending·0 cites
- 4250US2020325481A1Antisense-based therapeutics for targeting htra1 and methods of useGEMINI THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 4350US2009137506A1RNA Interference Mediated Inhibition of Cyclic Nucleotide Type 4 Phosphodiesterase (PDE4B) Gene Expression Using Short Interfering Nucleic Acid (siNA)SIRNA THERAPEUTICS INC·Filed 2008·Application pending·0 cites
- 4450US2010152278A1RNA Interference Mediated Inhibition of Cyclic Nucleotide Type 4 Phosphodiesterase (PDE4B) Gene Expression Using Short Interfering Nucleic Acid (siNA)MERCK & CO INC·Filed 2008·Application pending·0 cites
- 4550US2010120895A1RNA Interference Mediated Inhibition of Cyclic Nucleotide Type 4 Phosphodiesterase (PDE4B) Gene Expression Using Short Interfering Nucleic Acid (siNA)MERCK & CO INC·Filed 2008·Application pending·0 cites
- 4648US2010197763A1RNA Interference Mediated Inhibition of Cyclic Nucleotide Type 4 Phosphodiesterase (PDE4B) Gene Expression Using Short Interfering Nucleic Acid (siNA)MERCK & CO INC·Filed 2008·Application pending·0 cites
- 4746US2022396807A1Methods for treating patients having cfh mutations with cfh-encoding vectorsGEMINI THERAPEUTICS SUB INC·Filed 2020·Application pending·0 cites
- 4845US2024024416A1Methods for treating inflammatory ocular diseases with complement factor hGEMINI THERAPEUTICS SUB INC·Filed 2021·Application pending·0 cites
- 4935US2012022142A1RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 1 (STAT1) Gene Expression Using Short Interfering Nucleic Acid (siNA)JADHAV VASANT·Filed 2010·Application pending·0 cites
- 5033US2012029054A1RNA Interference Mediated Inhibition of GATA Binding Protein 3 (GATA3) Gene Expression Using Short Intefering Nucleic Acid (siNA)PICKERING VICTORIA·Filed 2010·Application pending·0 cites
Showing the top 50 of 58 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →